Sitagliptin/metformin (Janumet) as combination therapy in the treatment of type-2 diabetes mellitus

P and T

Volumn 37, Issue 12, 2012, Pages 699-708

  St Onge, Erin L ^a   Miller, Shannon ^b   Clements, Elizabeth ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450; DIGOXIN; EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MEGLITINIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL DISCOMFORT; ACUTE PANCREATITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIDIABETIC ACTIVITY; ARTICLE; ASTHENIA; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EDEMA; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HEADACHE; HUMAN; HYPOGLYCEMIA; INDIGESTION; INFLUENZA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FAILURE; METABOLIC ACIDOSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMACH DISCOMFORT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84872032911     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet, 2011. Available at: www.cdc.gov/diabetes/ pubs/pdf/ndfs_2011.pdf. Accessed May 30, 2012.
2. Inzucci, SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient centered approach: Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2012;35:1364-1379.
3. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2007;30:1374-1383.
4. FDA approves Janumet XR for type 2 diabetes, offering the powerful efficacy of Janumet now available with once-daily convenience. Available at: www.merck.com/newsroom/news-release-archive/ prescription-medicine-news/2012_0202.html. Accessed May 31, 2012.
5. Creutzfeldt W. The [pre] history of the incretin concept. Regul Pept 2005;128:87-91.
6. Weber A. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004;47:4135-4141.
7. Miller SA, St. Onge, E. Sitagliptin: A dipeptidyl peptidase inhibitor in the treatment of diabetes. Ann Pharmacother 2006;40(7-8);1336-1343.
8. VisbØll T, Krarup T, Deacon C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
9. Nauck MA, Vardaril I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia 2011;54:10-18.
10. Deacon CF. MK-431 (Merck). Curr Opin Investig Drugs 2005;6:419-426.
11. Langely AK, Suffoletta TJ, Jennings HR, et al. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007;27(8):1163-1180.
12. Januvia (sitagliptin), package insert. Whitehouse Station, N.J.: Merck; 2011. Available at: www.januvia.com/sitagliptin/januvia/ hcp/januvia/index.jsp?WT.svl=1. Accessed December 7, 2011.
13. Krentz AJ, Bailey CJ. Oral antidiabetic agents current role in type 2 diabetes mellitus. Drugs 2005;65(3):385-411.
14. Glucophage (metformin), package insert. Princeton, N. J: Bristol-Myers Squibb; 2009. Available at: http://packageinserts.bms.com/ pi/pi_glucophage.pdf. Accessed December 7, 2011.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998;352:854-865.
16. Brazg R, Xu L, Dalla MC, Cobelli C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and g-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-193.
17. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010 May;12(5):442-451.
18. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13(7):644-652.
19. Goldstein BJ, Feinglos MN, Johnson JJ, et al. Effect of initial combination therapy with sitagliptin, a dipeptidylpeptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.
20. Charbonnel B, Karasik A, Liu J, et al for the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29(12):2638-2643.
21. Perez-Montverde A, Seck T, Xu L, et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract 2011;65(9):930-938.
22. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24(2):537-550.
23. Karasik A, Wu M, Williams-Herman D, Meininger G. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss (Abstract 0523-P). American Diabetes Association, 67th Sessions, June 22-26, 2007, Chicago. Available at: http://professional.diabetes. org/Content/Posters/2007/p0523-P.pdf. Accessed June 6, 2012.
24. Nauck M, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, noninferiority trial. Diabetes Obes Metab 2007;9:194-205.
25. Scott R, Loeys T, Davies MJ, Engel SS, for the Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969.
26. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adults patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-549.
27. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-439.
28. VisbØll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12(2):167-177.
29. Janumet, prescribing information. Whitehouse Station, N.J.: Merck; 2007. Available at: www.merck.com/product/usa/pi_ circulars/j/janumet/janumet_pi.pdf. Accessed December 10, 2011.
30. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: A review of recent clinical trials. Curr Med Res Opin 2008;24(2):489-496.
31. Janumet XR, prescribing information. Whitehouse Station, N.J.: Merck; 2012. Available at: www.merck.com/product/usa/pi_ circulars/j/janumet_xr/janumet_xr_pi.pdf. Accessed March 2, 2012.
32. FDA Drug Safety Communication: Information for healthcare professionals: Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available at: www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764. htm. Accessed October 20, 2011.
33. Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: A case report. Diabet Med 2010;27(4):485-486.
34. Iyer SN, Drake AJ, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18(1):e10-3.
35. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963-1971.
36. Lewis JD, Ferrara A, Peng T, et al. Risks of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922.
37. FDA. Actos (pioglitazone). Available at: www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedical Products/ucm150451.htm?utm. Accessed June 5, 2012.
38. Kahn SE, Haffner SM, Heise MA, et al, for the ADOPT Study Group. Glycemia durability of rosiglitazone, metformin, or glyburide monotherapy. N Eng J Med 2006;355:2427-2443.
39. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: A 54-week study. Curr Med Res Opin 2009;25(3):569-583.
40. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733-745.